Hang GAO, Yazhou ZHAO, Chunying LIU. Treatment of IgA nephropathy based on the gut-kidney axis in traditional Chinese and Western medicine. [J]. Modern Chinese Clinical Medicine 29(2):72-76(2022)
DOI:
Hang GAO, Yazhou ZHAO, Chunying LIU. Treatment of IgA nephropathy based on the gut-kidney axis in traditional Chinese and Western medicine. [J]. Modern Chinese Clinical Medicine 29(2):72-76(2022) DOI: 10.3969/j.issn.2095-6606.2022.02.017.
Treatment of IgA nephropathy based on the gut-kidney axis in traditional Chinese and Western medicine
IgA nephropathy is the most common primary glomerular disease. The pathogenic association between the gut microbiota and IgA nephropathy (gut-kidney axis) has attracted much medical attention in recent years. Western medicine considers the gut microbiota as a potential source of toxins in uremia
and both dysfunction of the intestinal epithelial barrier and dysbiosis of the gut microbiota accelerate the progression of IgA nephropathy. Accordingly
treatment should include regulation of the intestinal microbiota and application of new therapeutic methods. Traditional Chinese medicine believes that the attack of pathogenic qi and the damage of healthy qi are the two factors that lead to the development of IgA nephropathy
and according to the characteristics of the course of IgA nephropathy
it is divided into the acute attack phase and the chronic maintenance phase. During acute attacks
bowels are supposed to be unblocked to expel the pathogenic factors
while during chronic maintenance
the healthy Qi should be protected.
关键词
IgA肾病肠肾轴肠道微生物中医西医
Keywords
IgA nephropathygut-kidney axisgut microbestraditional Chinese medicineWestern medicine
references
LIANG H, DAI Z, LIU N, et al. Dietary l-tryptophan modulates the structural and functional composition of the intestinal microbiome in weaned piglets[J]. Frontiers in Microbiology, 2018, 9(3):1736-1745.
MACIEL R A, REMPEL L C, BOSQUETTI B, et al. P-cresol but not p-cresyl sulfate stimulate MCP-1 production via NF-κB p65 in human vascular smooth muscle cells[J]. J Bras Nefrol, 2016, 38(2):153-160.
ZEISEL S H, WARRIER M. Trimethylamine N-Oxide, the microbiome, and heart and kidney disease[J]. Annu Rev Nutr, 2017, 37(2):157-181.
MAIR R D, SIRICH T L, PLUMMER N S, et al. Characteristics of colon-derived uremic solutes[J]. Clin J Am Soc Nephrol, 2018, 13(9):1398-1404.
YACOUB R, WYATT C M.Manipulating the gut microbiome to decrease uremic toxins[J]. Kidney Int, 2017, 91(3):521-523.
KIEFFER D A, PICCOLO B D, VAZIRI N D, et al.Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats[J]. Am J Physiol Renal Physiol, 2016, 310(9):857-871.
WU I W, GAO S S, CHOU H C, et al.Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease[J].Theranostics, 2020,10(12):5398-5411.
WANG Y F, ZHENG L J, LIU Y, et al.The gut microbiota-inflammation-brain axis in end-stage renal disease:perspectives from default mode network[J]. Theranostics, 2019, 9(26):8171-8181.
KAYAMA H, OKUMURA R, TAKEDA K. Interaction between the microbiota, epithelia, and immune cells in the intestine [J]. Annu Rev Immunol, 2020, 38(2):23-48.
KIRYLUK K, NOVAK J. The genetics and immunobiology of IgA nephropathy[J]. J Clin Invest, 2014, 124(6):2325-2332.
ZHAI Y L, ZHU L, SHI S F, et al.Increased april expression induces IgA1 aberrant glycosylation in IgA nephropathy[J]. Medicine, 2016, 95(11): 3099-3109.
EVENEPOEL P, POESEN R, MEIJERS B. The gut-kidney axis[J]. Pediatr Nephrol, 2017, 32(11):2005-2014.
MAHMOODPOOR F, RAHBAR SAADAT Y, BARZEGARI A, et al.The impact of gut microbiota on kidney function and pathogenesis[J]. Biomed Pharmacother, 2017, 93(3):412-419.
DE ANGELIS M, MONTEMURNO E, PICCOLO M, et al. Microbiota and metabolome associated with Immunoglobulin A Nephropathy (IgAN) [J]. PLoS One, 2014, 9(6): 990-1003.
BRITO J S, BORGES N A, DOLENGA C J, et al. Is there a relationship between tryptophan dietary intake and plasma levels of indoxyl sulfate in chronic kidney disease patients on hemodialysis? [J]. J Bras Nefrol, 2016, 38(4):396-402.
HAN L, FANG X, HE Y, et al. Isn forefronts symposium 2015:IgA nephropathy, the gut microbiota, and gut?kidney crosstalk [J]. Kidney International Reports, 2016, 1(3):189-196.
CHEMOUNY J M, GLEESON P J, ABBAD L, et al. Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice[J]. Nephrol Dial Transplant, 2019, 34(7):1135-1144.
JANA B, SALOMON D. Type Ⅵ secretion system: a modular toolkit for bacterial dominance[J]. Future Microbiol. 2019, 14(1):1451-1463.
SINGH N, GURAV A, SIVAPRAKASAM S, et al.Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis[J]. Immunity, 2014, 40(1):128-139.
FIORUCCI S, DISTRUTTI E. Bile acid-activated receptors,intestinal microbiota, and the treatment of metabolic disorders[J].Trends Mol Med, 2015,21(11):702-714.
JACOBSON A, LAM L, RAJENDRAM M, et al. A gut commensal-produced metabolite mediates colonization resistance to salmonella infection[J].Cell Host Microbe, 2018,24(2):296-307.
HUANG J, PEARSON J A, PENG J, et al.Gut microbial metabolites alter IgA immunity in type 1 diabetes[J]. JCI Insight, 2020, 5(10):e135718.
FRISBEE A L, PETRI W A, J R.Considering the immune system during fecal microbiota transplantation for clostridioides difficile infection [J]. Trends Mol Med, 2020, 26(5):496-507.
SANDERS M E, MERENSTEIN D J, REID G, et al. Probiotics and prebiotics in intestinal health and disease:from biology to the clinic[J].Nat Rev Gastroenterol Hepatol, 2019,16(10):605-616.
FLINT H J, DUNCAN S H, SCOTT K P, et al. Links between diet, gut microbiota composition and gut metabolism [J]. Proc Nutr Soc, 2015, 74(1):13-22.
SCHULMAN G, BERL T, BECK G J, et al.Randomized placebo-controlled EPPIC trials of ast-120 in CKD[J]. J Am Soc Nephrol, 2015, 26(7):1732-1746.
LI C, ZHANG J, XU H, et al. Effect of dahuang danpi decoction on lactobacillus bulgaricus growth and metabolism: in vitro study[J]. Medicine, 2019, 98(5):139-141.